Frequently asked questions
Which expression systems do you work with?
Our capabilities span CHO and HEK293 mammalian systems, as well as bacterial and yeast expression platforms, supporting biologics and advanced therapy applications.
Can you work with an existing cell line or microbial strain?
Yes. Programs can begin with de novo development or enter with an established client-owned cell line, strain, or process. We assess the available development and analytical data and define the appropriate path for transfer, optimization, scale-up, and manufacturing.
Can you support complex biologic modalities?
Yes. Our mammalian capabilities support monoclonal antibodies, bispecific and multispecific antibodies, fusion proteins, recombinant proteins, and other complex biologic formats.
How does cell line development connect with gene therapy?
Our advanced therapy capabilities include HEK293-based viral vector production systems, integrated with viral vector process development, plasmid DNA, analytics, banking, and manufacturing.
Can development continue into cGMP manufacturing?
Yes. Cell lines and microbial strains can progress within our integrated platform into process development, analytics, banking, scale-up, technology transfer, and cGMP manufacturing.
Where are these capabilities located?
Our development and manufacturing capabilities are integrated across our Vilnius, Lithuania, and Waltham, Massachusetts operations, connecting biologics and advanced therapy expertise according to program requirements.
